1990-2016年全球多发性硬化症负担的系统分析
该研究基于GBD 2016数据,量化1990-2016年全球多发性硬化症的流行病学负担及其与国家发展水平的关系。
核心结论
- 多发性硬化症不常见但可导致整个成年期的严重神经残疾,自1990年以来许多地区患病率大幅增加。
研究设计与样本
- 系统分析,使用DisMod-MR 2.1贝叶斯元回归框架建模1990-2016年多发性硬化症流行病学,死亡数据基于13 110站点-年生命登记数据。
主要发现
- 2016年多发性硬化症死亡18 932例(95% UI 16 577-21 033),DALY为1 151 478(968 605-1 345 776)。
- 1990-2016年年龄标化DALY随社会人口指数变化不一。
临床怎么用
- 研究结果可用于卫生服务的资源分配和规划。
- 全球许多地区多发性硬化症流行病学数据很少或没有,需要更多研究以做出更准确估计。
局限性
- 全球许多地区多发性硬化症流行病学数据很少或没有,需要更多研究以做出更准确估计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Multiple sclerosis is the most common inflammatory neurological disease in young adults. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) provides a systematic method of quantifying various effects of a given condition by demographic variables and geography. In this systematic analysis, we quantified the global burden of multiple sclerosis and its relationship with country development level. METHODS: We assessed the epidemiology of multiple sclerosis from 1990 to 2016. Epidemiological outcomes for multiple sclerosis were modelled with DisMod-MR version 2.1, a Bayesian meta-regression framework widely used in GBD epidemiological modelling. Assessment of multiple sclerosis as the cause of death was based on 13 110 site-years of vital registration data analysed in the GBD's cause of death ensemble modelling module, which is designed to choose the optimum combination of mathematical models and predictive covariates based on out-of-sample predictive validity testing. Data on prevalence and deaths are summarised in the indicator, disability-adjusted life-years (DALYs), which was calculated as the sum of years of life lost (YLLs) and years of life lived with a disability. We used the Socio-demographic Index, a composite indicator of income per person, years of education, and fertility, to assess relations with development level. FINDINGS: In 2016, there were 2 221 188 prevalent cases of multiple sclerosis (95% uncertainty interval [UI] 2 033 866-2 436 858) globally, which corresponded to a 10·4% (9·1 to 11·8) increase in the age-standardised prevalence since 1990. The highest age-standardised multiple sclerosis prevalence estimates per 100 000 population were in high-income North America (164·6, 95% UI, 153·2 to 177·1), western Europe (127·0, 115·4 to 139·6), and Australasia (91·1, 81·5 to 101·7), and the lowest were in eastern sub-Saharan Africa (3·3, 2·9-3·8), central sub-Saharan African (2·8, 2·4 to 3·1), and Oceania (2·0, 1·71 to 2·29). There were 18 932 deaths due to multiple sclerosis (95% UI 16 577 to 21 033) and 1 151 478 DALYs (968 605 to 1 345 776) due to multiple sclerosis in 2016. Globally, age-standardised death rates decreased significantly (change -11·5%, 95% UI -35·4 to -4·7), whereas the change in age-standardised DALYs was not significant (-4·2%, -16·4 to 0·8). YLLs due to premature death were greatest in the sixth decade of life (22·05, 95% UI 19·08 to 25·34). Changes in age-standardised DALYs assessed with the Socio-demographic Index between 1990 and 2016 were variable. INTERPRETATION: Multiple sclerosis is not common but is a potentially severe cause of neurological disability throughout adult life. Prevalence has increased substantially in many regions since 1990. These findings will be useful for resource allocation and planning in health services. Many regions worldwide have few or no epidemiological data on multiple sclerosis, and more studies are needed to make more accurate estimates. FUNDING: Bill & Melinda Gates Foundation.
引用
- Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019. PMID: 30679040. doi:10.1016/S1474-4422(18)30443-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。